The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Selective Drug Delivery System to Bone: Small Peptide (Asp)6 Conjugation
Abstract
Targeting a drug on hydroxyapatite (HA) could be a promising way for selective drug delivery to bone, because HA, an inorganic component in hard tissues (bone and teeth), does not exist in soft tissues. Several bone noncollagenous proteins, which bind to HA, have repeating sequences of acidic amino acids in their structures as possible HA-binding sites. Thus, we think that a small peptide of repetitive acidic amino acid could work as a carrier for selective drug delivery to the bone. To test this hypothesis, we conjugated (Asp)6 to fluorescein isothiocyanate (FITC), evaluated its affinity to HA in vitro, and examined its tissue distribution after injection into rats. Although fluorescein itself did not bind to HA, (Asp)6-FITC bound to HA as well as calceine and tetracycline. Twenty-four hours after intravenous injection of (Asp)6-FITC to rats, animals were killed, and ground sections of hard tissues and cryosections of soft tissues were made. Under a confocal laser scanning microscope, clear labeling lines were observed in bones and teeth, whereas no labeling was detected in soft tissues. In the rats administered with fluorescein alone, the fluorescent labeling was detected in neither hard nor soft tissues. Fluorescent analysis of blood, urine, and bones after (Asp)6-FITC administration revealed that biological half-life of FITC in blood was short (60 minutes) and that within 24 h, 95% of the administered FITC was excreted as urine whereas 2% of the FITC accumulated in bones. After subcutaneous administration of (Asp)6-FITC to mice, fluorescent intensity remaining in the femurs was measured periodically. In these mice the biological half-life of FITC in the femur was 14 days. Present results indicate that (Asp)6 is effective as a carrier for selective drug delivery to bone. (J Bone Miner Res 2000;15:936–943)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
Colditz, G. A., Hankinson, S. E., Hunter, D. J., Willett, W. C., Manson, J. E., Stampfer, M. J., Hennekens, C., Rosner, B., & Speizer, F. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506153322401 · Cited by 1,487 · cited 1×
“(1,2) A drug exhibiting the beneficial effects”
Cited by
Self‐Assembled Peptide‐Based Nanomaterials for Biomedical Imaging and Therapy
Qi, G., Gao, Y., Wang, L., & Wang, H. (2018) · Advanced Materials · doi:10.1002/adma.201703444 · Cited by 527
Alkaline Phosphatase and Hypophosphatasia
Millán, J. L., & Whyte, M. P. (2016) · Calcified Tissue International · doi:10.1007/s00223-015-0079-1 · Cited by 397
Localized delivery of growth factors for bone repair
Luginbuehl, V., Meinel, L., Merkle, H. P., & Gander, B. (2004) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2004.03.004 · Cited by 332
Bone-fracture-targeted dasatinib-oligoaspartic acid conjugate potently accelerates fracture repair
Wang, M., Park, S., Nam, Y., Nielsen, J., Low, S. A., Srinivasarao, M., & Low, P. S. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00660 · Cited by 24
Drug Delivery Based on Nanotechnology for Target Bone Disease
Yang, X., Chen, S., Liu, X., Yu, M., & Liu, X. (2019) · Current Drug Delivery · doi:10.2174/1567201816666190917123948 · Cited by 15
Metadata
- Authors
- Kasugai, S., Fujisawa, R., Waki, Y., Miyamoto, K.-I., & Ohya, K.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-05-01
- Volume
- 15
- Issue
- 5
- Pages
- 936-943
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2011350479
- Cited by
- 161
- References
- 1
- FWCI
- 1.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selective Drug Delivery System to Bone: Small Peptide (Asp)6 Conjugation. https://app.cochat.ai/papers/10.1359/jbmr.2000.15.5.936
- The paper
- Kasugai, S., Fujisawa, R., Waki, Y., Miyamoto, K.-I., & Ohya, K. (2000). Selective Drug Delivery System to Bone: Small Peptide (Asp)6 Conjugation. Journal of Bone and Mineral Research. https://doi.org/10.1359/jbmr.2000.15.5.936
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.